Correlation Between 4D Molecular and Cue Biopharma

Can any of the company-specific risk be diversified away by investing in both 4D Molecular and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 4D Molecular and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between 4D Molecular Therapeutics and Cue Biopharma, you can compare the effects of market volatilities on 4D Molecular and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 4D Molecular with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of 4D Molecular and Cue Biopharma.

Diversification Opportunities for 4D Molecular and Cue Biopharma

0.4

Correlation Coefficient

4D Molecular  Cue Biopharma

Very weak diversification

The 3 months correlation between FDMT and Cue is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding 4D Molecular Therapeutics and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and 4D Molecular is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 4D Molecular Therapeutics are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of 4D Molecular i.e., 4D Molecular and Cue Biopharma go up and down completely randomly.

Pair Corralation between 4D Molecular and Cue Biopharma

Given the investment horizon of 90 days 4D Molecular Therapeutics is expected to under-perform the Cue Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, 4D Molecular Therapeutics is 1.32 times less risky than Cue Biopharma. The stock trades about -0.12 of its potential returns per unit of risk. The Cue Biopharma is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  108.00  in Cue Biopharma on December 26, 2024 and sell it today you would lose (9.00) from holding Cue Biopharma or give up 8.33% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

4D Molecular Therapeutics  vs.  Cue Biopharma

4D Molecular Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days 4D Molecular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Cue Biopharma

Risk-Adjusted Performance

Weak

Over the last 90 days Cue Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Cue Biopharma is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.

Pair Trading with 4D Molecular and Cue Biopharma

The main advantage of trading using opposite 4D Molecular and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 4D Molecular position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.

The idea behind 4D Molecular Therapeutics and Cue Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.